Intech Investment Management LLC Reduces Holdings in Kymera Therapeutics, Inc. $KYMR

Intech Investment Management LLC cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 36.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,711 shares of the company’s stock after selling 8,279 shares during the period. Intech Investment Management LLC’s holdings in Kymera Therapeutics were worth $833,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after buying an additional 1,833 shares during the last quarter. Millennium Management LLC increased its position in shares of Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after acquiring an additional 491,737 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Kymera Therapeutics by 5.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after acquiring an additional 59,347 shares during the last quarter.

Insider Transactions at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,576 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $673,733.68. Following the transaction, the chief financial officer owned 237,483 shares of the company’s stock, valued at approximately $21,119,363.19. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 2,005,813 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average cost of $86.00 per share, for a total transaction of $172,499,918.00. Following the completion of the purchase, the director directly owned 7,955,916 shares in the company, valued at $684,208,776. This trade represents a 33.71% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 407,391 shares of company stock worth $36,650,485 over the last three months. 16.01% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on KYMR shares. Morgan Stanley restated an “overweight” rating and set a $123.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Bank of America boosted their price objective on Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Piper Sandler raised their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $85.04 on Tuesday. The business has a 50-day moving average of $78.89 and a two-hundred day moving average of $67.44. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of -23.11 and a beta of 2.20. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company’s quarterly revenue was down 60.8% on a year-over-year basis. During the same period last year, the business earned ($0.88) earnings per share. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.